Equity Overview
Price & Market Data
Price: $10.25
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $2,321,585,408
Daily Volume: 0
Performance Metrics
1 Week: 1.43%
1 Month: 9.70%
3 Months: -0.58%
6 Months: -14.80%
1 Year: 43.96%
YTD: 0.59%
Company Details
Employees: 1795
Sector: Health technology
Industry: Biotechnology
Country: Denmark
Details
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.